Masimo Co. (NASDAQ:MASI) Holdings Raised by Picton Mahoney Asset Management

Picton Mahoney Asset Management grew its position in Masimo Co. (NASDAQ:MASI) by 194.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,610 shares of the medical equipment provider’s stock after acquiring an additional 28,153 shares during the quarter. Picton Mahoney Asset Management’s holdings in Masimo were worth $7,044,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp bought a new position in shares of Masimo in the fourth quarter worth $27,000. UMB Bank n.a. grew its stake in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new position in shares of Masimo in the fourth quarter worth $33,000. Blue Trust Inc. grew its stake in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Trading Up 1.5 %

Shares of NASDAQ MASI opened at $168.21 on Friday. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a market cap of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.03. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The business has a fifty day simple moving average of $174.84 and a 200-day simple moving average of $157.65.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Sell-side analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Analyst Ratings Changes

MASI has been the subject of several research analyst reports. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Wells Fargo & Company upped their price objective on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Piper Sandler upped their price objective on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company’s stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.